ERBB2 and breast carcinoma: These results are consistent with previous observations from our laboratory, where we found that treatment with antiestrogens and the tyrosine kinase inhibitor lapatinib led to the upregulation of ERα in ER-negative/HER2-positive breast cancer cells [28].